SCM
CGEM icon

Silverarc Capital Management’s Cullinan Oncology CGEM Stock Holding History

Silverarc Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-265,032
Closed -$2.71M – 88
2023
Q1 		$2.71M Buy
265,032
+35,616
+16% +$393K 1.22% 34
2022
Q4 		$2.42M Buy
229,416
+4,861
+2% +$59K 0.83% 50
2022
Q3 		$2.88M Buy
224,555
+11,465
+5% +$154K 1.22% 35
2022
Q2 		$2.73M Buy
+213,090
New +$2.42M 1.28% 33
2021
Q3 		– Sell
-75,732
Closed -$1.95K – 89
2021
Q2 		$1.95K Buy
+75,732
New +$2.33M 0.95% 41

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return